Figure 5.
Effects of CCL5 on breast cancer cells. A, CCK8 determined cell viability in SKBR‐3 and SKBR‐3/SI cells following treatment with 10 pg/mL recombinant human CCL5 and neutralizing CCL5 ab for 72 h. IC50 values are presented in the mini‐tables. B,C, Cell proliferation and apoptosis of SKBR‐3 and SKBR‐3/SI cells treated by 10 pg/mL recombinant human CCL5 and neutralizing CCL5 ab by colony formation assay and flow cytometry, respectively. D, Wound‐healing assay indicated cell migration of SKBR‐3 and SKBR‐3/SI treated with 10 pg/mL CCL5 or neutralizing CCL5 ab. E, Migration assay of SKBR‐3 and SKBR‐3/SI treated with CCL5 or CCL5 ab was performed. The error bars represent the mean of 3 separate determinations ± SD. **P < .01, ***P < .001